Post-TAVR patients on GLP-1 drugs had lower mortality, while those on both GLP-1 and SGLT2 inhibitors had reduced mortality, heart attacks, heart failure hospitalizations, and arrhythmias.
Combination benefitGLP-1 RA + SGLT2i together reduced mortality, MI, heart failure, and arrhythmia after heart valve replacement
What the researchers found
Post-TAVR: GLP-1 RA decreased all-cause mortality; SGLT2i decreased arrhythmia; combined GLP-1 RA + SGLT2i decreased mortality, MI, acute HF, and arrhythmia compared to untreated matched controls.
Why it matters
TAVR patients face high cardiovascular risk with limited evidence-based medical therapy. Adding GLP-1 drugs could improve survival in this growing patient population.
How the study worked
Retrospective propensity-matched cohort study using TriNetX database, comparing post-TAVR patients on GLP-1 RA, SGLT2i, both, or neither, with Kaplan-Meier survival analysis.
What this study cannot tell us
Retrospective observational design. TAVR patients on these drugs may have different baseline characteristics. Cannot determine optimal timing to start therapy. Specific hazard ratios not provided in abstract.
How to read the evidence
Retrospective propensity-matched study. Consistent benefits across multiple outcomes support the hypothesis, but prospective validation needed.
When this study was published
Published in 2025.
The bigger picture
This extends the cardiovascular benefits of GLP-1 drugs to the structural heart disease population, suggesting broad cardioprotection across diverse cardiac conditions.
Questions still open
- Should GLP-1 drugs be standard care after TAVR?
- What is the optimal timing to initiate GLP-1 therapy relative to TAVR?
- Would a dedicated RCT of GLP-1 drugs in TAVR patients be feasible?
Common questions
Should I take GLP-1 drugs after heart valve replacement?
Why would diabetes drugs help after heart valve surgery?
Read the original research
Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor with Cardiovascular Outcomes after Transcatheter Aortic Valve Replacement.
The American journal of cardiology
Citation
Fahoury, Alan M; Kamel-Abusalha, Louie; Didier, Alexander J; Wunderly, Kevin; Sarrouj, Sami; Issa, Rochell; Afifi, Ahmed; Gupta, Rajesh. (2026). Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor with Cardiovascular Outcomes after Transcatheter Aortic Valve Replacement.. The American journal of cardiology. https://doi.org/10.1016/j.amjcard.2026.02.043